Publisher
Springer Science and Business Media LLC
Reference155 articles.
1. Lauret A, Molto A, Abitbol V, Gutermann L, Conort O, Chast F, et al. Effects of successive switches to different biosimilars infliximab on immunogenicity in chronic inflammatory diseases in daily clinical practice. Semin Arthritis Rheum. 2020;50(6):1449–56.
2. Thomas L. Biosimilars: providing more treatment options. 2019. https://www.bio-rad.com/webroot/web/pdf/lsr/literature/Bulletin_7071.pdf. Accessed 5 Nov 2019.
3. Al Sulais E, AlAmeel T. Biosimilars to antitumor necrosis factor agents in inflammatory bowel disease. Biologics Targets Therapy. 2020;14:1–11.
4. Kim H, Alten R, Avedano L, Dignass A, Gomollon F, Greveson K, et al. The future of biosimilars: maximizing benefits across immune-mediated inflammatory diseases. Drugs. 2020;80(2):99–113.
5. Smeeding J, Malone DC, Ramchandani M, Stolshek B, Green L, Schneider P. Biosimilars: considerations for payers. P&T Peer-Rev J Formul Manage. 2019;44(2):54–63.
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献